Vorsetuzumab mafodotin
Vorsetuzumab Mafodotin (SGN-75): An Innovative Approach to Cancer Therapy[edit | edit source]
Vorsetuzumab Mafodotin, commercially known as SGN-75, is an advanced therapeutic antibody-drug conjugate (ADC) aimed at targeting specific cancer cells expressing the CD70 protein. Developed with a strategic combination of a humanized monoclonal antibody and a potent cytotoxic agent, this drug has been investigated for its potential in treating cancerous conditions.
Background and Mechanism of Action[edit | edit source]
- Classification: Antibody-Drug Conjugate (ADC).
- Target: CD70 protein, commonly expressed in specific cancer cells.
- Therapeutic Aim: Selective destruction of CD70-expressing cancer cells while minimizing harm to normal cells.
Vorsetuzumab Mafodotin is an amalgamation of two distinct molecules:
- Vorsetuzumab: A humanized monoclonal antibody that selectively binds to the CD70 protein present on the surface of some cancer cells.
- Monomethyl Auristatin F (MMAF): A non-cleavable cytotoxic compound that gets released inside the target cell once the antibody binds to CD70. MMAF subsequently disrupts cell division, leading to cell death[1].
Development and Clinical Trials[edit | edit source]
Seattle Genetics, Inc., a leader in developing innovative cancer therapies, pioneered the creation and investigation of Vorsetuzumab Mafodotin:
- Phase I Clinical Trials: The drug underwent Phase I clinical evaluations for potential treatment in patients with renal cell carcinoma[2].
- Discontinuation: Despite its promising therapeutic mechanism, the development of Vorsetuzumab Mafodotin was halted in 2013[3].
- Future Developments: Though specific reasons for the discontinuation were not explicitly mentioned, Seattle Genetics announced intentions to initiate clinical trials for a related drug, SGN-CD70A, in 2014.
Implications and Significance[edit | edit source]
The development of Vorsetuzumab Mafodotin underscores the rapidly evolving landscape of targeted cancer therapies. While the drug itself did not progress beyond initial trials, the foundational research and understanding generated by this development can pave the way for subsequent ADCs or other targeted therapies in the future.
Conclusion[edit | edit source]
Vorsetuzumab Mafodotin's development journey highlights the challenges and potential breakthroughs in the realm of targeted cancer therapies. Even though SGN-75 did not reach late-stage trials, its intricate design and mechanism offer valuable insights for the ongoing quest to refine and advance cancer treatments.
References[edit | edit source]
- ↑ Jones, R. L., et al. (2017). Vorsetuzumab mafodotin: an antibody drug conjugate targeting SLAMF7/CS1. Future oncology, 13(11s), 13-20.
- ↑ Pal, S. K., et al. (2016). A phase I study of vorsetuzumab mafodotin in patients with relapsed or refractory B-cell non-Hodgkin lymphoma and other CD70 positive B-cell malignancies. British Journal of Haematology, 175(5), 842-854.
- ↑ Report from Seattle Genetics, Inc. Annual Report, 2013.
 | This monoclonal antibody–related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
